Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,860 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: DEXAMETHASONE Clear all
Terminated Phase 1Phase 2 Interventional Results available

Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies

NCT02906670
View directory record Official record
Conditions
Oncology
Interventions
Sym013
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 5, 2026, 4:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of a Bilateral TAP Block and Preperitoneal Instillation of Local Anesthetic for a Total Extraperitoneal (TEP) Repair

NCT02036983
View directory record Official record
Conditions
Bilateral Inguinal Hernia Repair
Interventions
Transversus abdominis plane block (TAP BLOCK), Instillation of surgical site with local anesthetic., Opioid IV medications (Control)
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 5, 2026, 4:35 AM EDT
Recruiting Early Phase 1 Interventional

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

NCT03719105
View directory record Official record
Conditions
NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
Interventions
Methotrexate, pralatraxate,, Ifosfamide, Dexamethasone, Etoposide, calaspargase pegol, cyclophosphamide, Doxorubicin, Prednisone, Brentuximab Vedotin
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Year to 31 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 5, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT03391466
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
30
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 5, 2026, 4:35 AM EDT
Recruiting Phase 2 Interventional

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

NCT05469893
View directory record Official record
Conditions
High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
Interventions
Teclistamab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Irene Ghobrial, MD
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
3
States / cities
Denver, Colorado • Boston, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 5, 2026, 4:35 AM EDT
Recruiting Phase 4 Interventional

Multifidus Cervicis Plane Block Vs. Sham Block For Posterior Cervical Spine Fusion Surgery

NCT05996133
View directory record Official record
Conditions
Cervical Spine Fusion
Interventions
Bupivacaine Hcl 0.25% Inj, Normal saline
Drug · Other
Lead sponsor
Hartford Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 5, 2026, 4:35 AM EDT
Terminated Not applicable Interventional Results available

The Effect of Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine or Bupivacaine

NCT00801138
View directory record Official record
Conditions
Anesthesia, Local, Shoulder Surgery
Interventions
saline, Dexamethasone, ropivacaine, Bupivacaine
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2017 · Synced Sep 5, 2026, 4:35 AM EDT
Completed Phase 1 Interventional Results available

Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)

NCT00866307
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Prophylactic Cranial Irradiation, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
25
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 5, 2026, 4:35 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma

NCT01484626
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bendamustine
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 5, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00103285
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
3-Dimensional Conformal Radiation Therapy, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate
Radiation · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
5,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
210
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 5, 2026, 4:35 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT03701321
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab, Dexamethasone, Venetoclax
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Indianapolis, Indiana • Rochester, Minnesota • Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Sep 5, 2026, 4:35 AM EDT
Completed Phase 1 Interventional

Efficacy of Percutaneous SPG Block in Aneurysmal SAH

NCT04331938
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Headache
Interventions
Regional anesthetic SPG block-bilateral
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 5, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery

NCT03192150
View directory record Official record
Conditions
Inflammation and Pain Associated With Cataract Surgery
Interventions
ISV-305, Vehicle
Drug · Other
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
17 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 5, 2026, 4:35 AM EDT
Completed Phase 1 Interventional Results available

A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects

NCT01980589
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Cyclophosphamide, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
9
States / cities
Encinitas, California • West Hollywood, California • Whittier, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 5, 2026, 4:35 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00005596
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
1,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
108
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 5, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa

NCT02216071
View directory record Official record
Conditions
Acute Otitis Externa
Interventions
Ciprodex®, EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension
Drug
Lead sponsor
Exela Pharma Sciences, LLC.
Industry
Eligibility
6 Months and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
46
States / cities
Birmingham, Alabama • Mesa, Arizona • Jonesboro, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 5, 2026, 4:35 AM EDT
Terminated Phase 2 Interventional

Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma

NCT00005987
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
carmustine, cyclophosphamide, dexamethasone, etoposide, filgrastim, mitoxantrone hydrochloride, recombinant interferon alfa, sargramostim, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 5, 2026, 4:35 AM EDT
Withdrawn Phase 2 Interventional

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

NCT06060587
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, ADT, Abiraterone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 5, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina

NCT04976777
View directory record Official record
Conditions
Macular Edema
Interventions
Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
Device · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Glendale, California • North Dartmouth, Massachusetts • Independence, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 5, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)

NCT00617591
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Pegylated Liposomal Doxorubicin (PLD), Dexamethasone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Sep 5, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

NCT01023308
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Panobinostat, Bortezomib, Dexamethasone, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
38
States / cities
Phoenix, Arizona • Anaheim, California • Concord, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Sep 5, 2026, 4:35 AM EDT
Terminated Phase 2 Interventional Results available

Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00524589
View directory record Official record
Conditions
Prostate Cancer
Interventions
calcitriol, dexamethasone, protein expression analysis, laboratory biomarker analysis
Dietary Supplement · Drug · Genetic + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 120 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 5, 2026, 4:35 AM EDT
Withdrawn Phase 4 Interventional

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

NCT02130817
View directory record Official record
Conditions
End Stage Renal Disease, Antibody Mediated Rejection
Interventions
Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Sep 5, 2026, 4:35 AM EDT
Terminated Phase 4 Interventional Results available

Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation

NCT03247413
View directory record Official record
Conditions
Neuritis, Radiofrequency Ablation
Interventions
Dexamethasone 4 mg/ml, Normal saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 5, 2026, 4:35 AM EDT